Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) confirms it has no financial exposure to Silicon Valley Bank, which was closed by California authorities. All cash and investments remain secure, unaffected by the bank's receivership. The company has an At-The-Market (ATM) program with SVB Securities, which operates independently and is not impacted by the closure. Innate Pharma maintains a robust liquidity position, ensuring ongoing operations will continue without disruption.
As of February 1, 2023, Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reports a total of 80,213,957 ordinary shares outstanding. Additionally, there are 6,514 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights stands at 80,971,797, while exercisable voting rights amount to 80,953,222. Innate Pharma specializes in developing therapeutic antibodies targeting cancer, with a focus on natural killer cell biology and tumor microenvironments, collaborating with major biopharmaceutical companies.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced participation in several upcoming investor conferences, focusing on oncology advancements. The conferences include:
- SVB Securities Global Biopharma Conference: February 14-16, 2023 (virtual)
- Citi's 2023 Virtual Oncology Leadership Summit: February 22, 2023 (virtual)
- H.C. Wainwright Cell Therapy Virtual Conference: February 28, 2023 (virtual)
Innate Pharma specializes in therapeutic antibodies aimed at enhancing cancer treatment. The company is recognized for its innovative approach, particularly regarding Natural Killer cell biology, and maintains significant partnerships with industry leaders.
Innate Pharma announced the expiration of the Hart-Scott-Rodino waiting period, making its licensing agreement with Sanofi effective. This collaboration involves Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKET® platform. The agreement includes a €25 million upfront payment and up to €1.35 billion in potential milestones, plus royalties on net sales. The ANKET® technology is designed to enhance cancer treatment by utilizing NK cells. Innate Pharma aims to leverage its innovative approach in oncology to address unmet medical needs.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) recently announced promising preclinical results published in Nature Biotechnology, demonstrating significant control of acute myeloid leukemia (AML) using a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. These findings indicate that CD123-NKCE can activate NK cells effectively against AML cells while minimizing toxicity. A Phase 1/2 clinical trial is currently underway, evaluating IPH6101/SAR’579 in patients with relapsed or refractory AML. Experts express optimism about its potential superiority over existing treatments.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has expanded its collaboration with Sanofi (NASDAQ: SNY) by granting an exclusive license for its B7H3 ANKETTM program. Sanofi will be accountable for all development and commercialization activities. Innate will receive an upfront payment of €25 million and up to €1.35 billion in potential milestones, along with royalties from net sales. This partnership continues the 2016 collaboration focused on NK cell engagers, enhancing Innate's cancer treatment portfolio and Sanofi's oncology strategy.
Innate Pharma, listed on Nasdaq under the ticker IPHA, recently presented encouraging results from the TELLOMAK Phase 2 trial of lacutamab for treating Sézary syndrome, demonstrating an objective response rate (ORR) of 21.6% in the intention to treat (ITT) population. In blood samples, the ORR was 37.8%, while skin samples showed 35.1% ORR. Lacutamab maintains a favorable safety profile with low incidence of severe treatment-related adverse events. The company aims to further explore lacutamab's efficacy in other T-cell lymphomas.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has provided an update on its outstanding shares as of December 1, 2022. The company reports a total of 80,812,069 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights is 80,969,909, while the exercisable voting rights are noted as 80,951,334. This disclosure aligns with French stock-market regulations and aims to keep the market informed about the company’s capital structure.
Innate Pharma announced three poster presentations at the ESMO Immuno-Oncology Annual Congress on December 8, 2022, in Geneva, Switzerland. The posters include Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, presented by AstraZeneca, and preclinical data supporting its Phase 2 development in non-small cell lung cancer. The IPH5301, a CD73-blocking antibody, will also be showcased along with the trial design.
Innate Pharma reported a cash position of €151.4 million as of September 30, 2022, ensuring a cash runway into H2 2024. The company showcased preliminary data from the Phase 2 TELLOMAK trial of lacutamab, highlighting a clinical activity with a global objective response rate (ORR) of 28.6% in mycosis fungoides. Additionally, lacutamab's ongoing Phase 2 data in Sézary syndrome is set to be presented at the ASH 2022 Annual Congress on December 10. Revenues for the first nine months of 2022 reached €44.3 million, compared to €10.3 million for the same period in 2021.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
